Fig. 6: 6-TG reduces S. aureus toxin production in a purine-dependent and -independent manner.

a S. aureus was grown in the presence of 6-TG (10 µg/mL) or a vehicle control to an OD₆₀₀ of 7.0 and secreted proteins in the supernatant were TCA precipitated and separated by SDS-PAGE. This experiment was repeated three times with similar results. b Protein samples in a were immunoblotted and probed with anti-alpha toxin antibody in a Western blot. Protein identification was by MALDI TOF MS. Numbers indicate molecular mass markers. This experiment was repeated three times with similar results. c S. aureus and S. aureus purK::ΦΝΣ was grown in TSB with 6-TG (10 µg/mL) or a vehicle control to an OD₆₀₀ of 7.0 and secreted proteins in the supernatant were TCA precipitated and separated by SDS-PAGE. This experiment was repeated twice with similar results. d Protein samples in c were immunoblotted and probed with anti-alpha toxin antibody in a Western blot. This experiment was repeated twice with similar results. e Quantitation of necrotic skin lesion size 4 days post infection with S. aureus or S. aureus purK::ΦΝΣ ± prophylactic 6-TG (20 µg) treatment. Results are from one representative experiment with 16 lesions enumerated per group (n = 8 animals). Data are shown as mean ± SD (***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05. Two-sided unpaired t-test). f Skin tissue was excised from mice infected with S. aureus or S. aureus purK::ΦΝΣ 4 days post infection ± prophylactic 6-TG (20 µg) treatment and plated onto TSA to enumerate CFUs. Results are from one representative experiment with 16 lesions enumerated per group (n = 8 animals). Data are shown as mean ± SD (***p ≤ 0.001. Two-sided unpaired t-test). For a–d, numbers to the left of gels/blots are molecular mass markers (in kDa).